Advertisement Pharmaceutical Business review - Page 61 of 5255 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
December 22, 2025

MEDIPOST, Teikoku Seiyaku partner for CARTISTEM commercialisation in Japan

MEDIPOST has announced a multi-year exclusive partnership with Teikoku Seiyaku to commercialise CARTISTEM, an allogeneic stem cell therapy for moderate to severe knee osteoarthritis, in Japan.

MEDIPOST global business division head and co-CEO Antonio Seung Jin Lee, and Teikoku Seiyaku international business board member and senior managing director Akira Nakagawa. Credit: MEDIPOST/PR Newswire.